• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    International companies to host live webcasts at Deutsche Bank's Depositary Receipts

    11/1/23 8:35:00 AM ET
    $BLTE
    $HYW
    $IH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance
    Get the next $BLTE alert in real time by email

    NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Wednesday, November 8 and Thursday, November 9, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US.

    Representatives from participating companies based in Australia, China, France, Germany, Greece, Hong Kong, Netherlands, Philippines and Taiwan will respond to questions during formal presentations and will also interact with investors via virtual trade booths. The conference is targeted to all categories of investors and analysts interested in non-US companies.

    There is no fee for participants to log in, attend live presentations and/or ask questions.

    Please register via this link: www.adr.db.com/dbvic

    Pre-registration is suggested.

    November 8 Agenda (US Eastern Standard Time):

    • 8:00 AM: Hywin Holdings Ltd (NASDAQ:HYW)
    • 8:30 AM: European Metals Holding Limited ((ASX &, LON: EMH, OTCQX:ERPNF, OTCQX:EMHXY)
    • 9:00 AM: Ipsen S.A. Ltd (PARIS:IPN, OTC:IPSEY)
    • 9:30 AM: Heineken N.V. ((Euronext Amsterdam: HEIA, OTCQX:HEINY)
    • 10:00 AM: First Pacific Company Ltd ((HKEX: 142, OTC:FPAFY)
    • 10:30 AM: QBE Insurance Group Limited ((ASX: QBE, OTC:QBIEY)
    • 11:00 AM: Belite Bio, Inc (NASDAQ:BLTE)

    November 9 Agenda (US Eastern Standard Time):

    • 8:00 AM: iHuman Inc. (NYSE:IH)
    • 8:30 AM: HUTCHMED (China) Limited (HKEX: 13, Nasdaq & AIM:​HCM)
    • 9:00 AM: BDO Unibank, Inc ((PSE: BDO, OTC:BDOUY)
    • 10:00 AM: Alpha Bank ((ATHEX: ALPHA, OTC:ALBKY)
    • 10:30 PM: Hugo Boss ((Xetra: BOSS, OTC:BOSSY)

    The presentations will be available for replay after the Conference.

    In addition to specializing in administering cross-border equity structures such as American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. The Bank offers a broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

    Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany's leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

    Deutsche Bank is sponsoring the Deutsche Bank Depositary Receipt Investor Conference solely for informational purposes. Deutsche Bank does not prepare, review, approve or edit any presentations, statements, documents or other information or materials, whether in written, electronic or verbal form, provided by any company participating in such conference, and disclaims any responsibility for the accuracy or adequacy of any such information or materials. Deutsche Bank is not promoting, endorsing or recommending any company participating in the conference.

    The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© November 2023 Deutsche Bank AG. All rights reserved.



    For further information, please contact
    Dylan Riddle
    Deutsche Bank AG
    Press & Media Relations
    Tel. +12122504982
    Cell. +1(904)3866481
    Email [email protected]
    Get the next $BLTE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLTE
    $HYW
    $IH

    CompanyDatePrice TargetRatingAnalyst
    Belite Bio Inc
    $BLTE
    1/26/2026$195.00Buy
    BofA Securities
    Belite Bio Inc
    $BLTE
    1/6/2026$191.00Overweight
    Morgan Stanley
    Belite Bio Inc
    $BLTE
    12/2/2025$194.00Neutral → Outperform
    Mizuho
    Belite Bio Inc
    $BLTE
    11/24/2025$154.00Overweight
    Cantor Fitzgerald
    Belite Bio Inc
    $BLTE
    11/20/2025$105.00Neutral
    Mizuho
    Belite Bio Inc
    $BLTE
    12/14/2023$60.00Buy
    Maxim Group
    Belite Bio Inc
    $BLTE
    7/28/2023$43.00Overweight
    Cantor Fitzgerald
    Belite Bio Inc
    $BLTE
    7/26/2023$25.00Outperform
    SVB Securities
    More analyst ratings

    $BLTE
    $HYW
    $IH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Belite Bio with a new price target

    BofA Securities initiated coverage of Belite Bio with a rating of Buy and set a new price target of $195.00

    1/26/26 10:01:23 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Belite Bio with a new price target

    Morgan Stanley initiated coverage of Belite Bio with a rating of Overweight and set a new price target of $191.00

    1/6/26 8:54:10 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio upgraded by Mizuho with a new price target

    Mizuho upgraded Belite Bio from Neutral to Outperform and set a new price target of $194.00

    12/2/25 8:17:09 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $HYW
    $IH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chen Wan-Shan

    4 - BELITE BIO, INC (0001889109) (Issuer)

    4/2/26 4:15:12 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chuang Hao-Yuan

    4 - BELITE BIO, INC (0001889109) (Issuer)

    4/2/26 4:15:10 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Mata Nathan L.

    4 - BELITE BIO, INC (0001889109) (Issuer)

    4/2/26 4:15:09 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $HYW
    $IH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

    SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 31, 2026, is available through its website (https://www.belitebio.com). Shareholders may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C). About Belite

    3/31/26 8:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

    BEIJING, March 31, 2026 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025.  Fourth Quarter 2025 HighlightsRevenues were RMB190.7 million (US$27.3 million), compared with RMB232.7 million in the same period last year.Gross profit was RMB127.5 million (US$18.2 million), compared with RMB156.4 million in the same period last year.Operating income was RMB9.0 million (US$1.3 mill

    3/31/26 6:06:00 AM ET
    $IH
    Other Consumer Services
    Real Estate

    Belite Bio to Participate in the Leerink Global Healthcare Conference

    SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc  (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Leerink Global Healthcare Conference on Monday, March 9, 2026 at 1:00 pm ET. Webcast Link InstructionsA webcast of each presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replays will be archived for 90 days followin

    3/2/26 8:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $HYW
    $IH
    SEC Filings

    View All

    SEC Form 6-K filed by iHuman Inc.

    6-K - iHuman Inc. (0001814423) (Filer)

    3/31/26 8:19:32 AM ET
    $IH
    Other Consumer Services
    Real Estate

    SEC Form 6-K filed by Belite Bio Inc

    6-K - BELITE BIO, INC (0001889109) (Filer)

    3/31/26 8:01:39 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Belite Bio Inc

    20-F - BELITE BIO, INC (0001889109) (Filer)

    3/31/26 8:00:40 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $HYW
    $IH
    Leadership Updates

    Live Leadership Updates

    View All

    Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

    Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appointed Hendrik P. N. Scholl, MD, MA, as the Chief Medical Officer of the Company, effective immediately. Dr. Scholl is the foremost globally recognized authority on Stargar

    9/1/24 8:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hywin Holdings Appoints New Independent Director

    SHANGHAI, China, June 27, 2022 (GLOBE NEWSWIRE) -- Hywin Holdings Ltd. ("Hywin Wealth", "Hywin", or the "Company") (NASDAQ:HYW), a leading independent wealth management service provider in China, today announced that Mr. Vincent Chun Hung Chan has been appointed to its Board of Directors, effective June 27, 2022. Mr. Vincent Chun Hung Chan will be serving as an independent non-executive director of the Company. With over 28 years of experience in private equity in Asia, Mr. Chan has been the Director of Samena Capital, which principally engages in private equity investment, since March 2021 and was a Senior Managing Director and Head of Asia of Samena Capital from 2016 to 2021. From 1991

    6/27/22 6:00:00 AM ET
    $HYW
    Investment Managers
    Finance

    $BLTE
    $HYW
    $IH
    Financials

    Live finance-specific insights

    View All

    iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

    BEIJING, March 31, 2026 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025.  Fourth Quarter 2025 HighlightsRevenues were RMB190.7 million (US$27.3 million), compared with RMB232.7 million in the same period last year.Gross profit was RMB127.5 million (US$18.2 million), compared with RMB156.4 million in the same period last year.Operating income was RMB9.0 million (US$1.3 mill

    3/31/26 6:06:00 AM ET
    $IH
    Other Consumer Services
    Real Estate

    iHuman Inc. Announces Third Quarter 2025 Unaudited Financial Results

    BEIJING, Dec. 29, 2025 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Revenues were RMB205.8 million (US$28.9 million), compared with RMB239.4 million in the same period last year.Gross profit was RMB140.6 million (US$19.8 million), compared with RMB163.9 million in the same period last year.Operating income was RMB16.7 million (US$2.3 million), compared

    12/29/25 4:11:00 AM ET
    $IH
    Other Consumer Services
    Real Estate

    New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

    Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033Tinlarebant met the primary efficacy endpoint, demonstrating clinical benefit by significantly reducing the lesion growth rate by 36% compared to placebo, as measured by retinal imagingTinlarebant was well tolerated throughout the trial Stargardt disease impacts more than 50,000 patients in the U.S. Belite Bio plans to file an NDA with the US FDA in 1H 2026Company will host a conference call and webcast today at 8:00 a.m. ET SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite

    12/1/25 6:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $HYW
    $IH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Belite Bio Inc

    SC 13G - BELITE BIO, INC (0001889109) (Subject)

    2/12/24 9:08:25 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Belite Bio Inc

    SC 13G - BELITE BIO, INC (0001889109) (Subject)

    2/12/24 8:40:46 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Belite Bio Inc

    SC 13G - BELITE BIO, INC (0001889109) (Subject)

    2/15/23 1:36:20 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care